Home » Cosmetic surgery » AVTD freezes its EOS device design for regulatory phase ArtVentive Medical Group.

announced today that the business offers frozen its Endoluminal Occlusion device style for the peripheral group of indications in planning for the business’s regulatory phase, ahead of commercialization in North and European countries America and after venturing ahead into Eastern Europe, Japan, Asia Pacific and Latin America. ‘That is another milestone in the business’s growth and movements the Company one step closer to its targeted 2011 European commercialization of the EOS device,’ stated Jim Graham, CEO, ArtVentive Medical Group, Inc. ‘We are pleased with the compounding success that we have experienced and we look forward to the continued expansion of us of EOS devices.’.. AVTD freezes its EOS device design for regulatory phase ArtVentive Medical Group, Inc.Atkins, M.D., Luis Baez-Diaz, M.D., Adam M. Brufsky, M.D., Ph.D., Rita S. Mehta, M.D., Louis Fehrenbacher, M.D., James A. Little, M.D., Francis M. Senecal, M.D., Rakesh Gaur, M.D., M.P.H., Richard G. Margolese, M.D., C.M., Paul T. Adams, M.D., Howard M. Gross, M.D., Joseph P. Costantino, Dr.P.H., Sandra M. Swain, M.D., Eleftherios P. Mamounas, M.D., and Norman Wolmark, M.D.: Bevacizumab Added to Neoadjuvant Chemotherapy for Breasts Cancer Neoadjuvant chemotherapy is becoming established as an acceptable option to adjuvant chemotherapy for operable breasts cancer, because the rates could be increased by it of breast-conserving surgery1-3 and decrease the dependence on complete axillary lymph-node dissection.4-6 Neoadjuvant chemotherapy offers the potential for rapidly testing regimens that may improve response prices and therefore may be likely to improve the outcomes in individuals.